BRAF Kinase Inhibitors Market Introduction
BRAF is a human gene that encodes the BRAF protein. The BRAF protein is more formally known as serine/threonine-protein kinase BRAF. The BRAF gene is also known as VRAF murine sarcoma viral oncogene homolog B and proto-oncogene BRAF. BRAF is a member of the RAF kinase family of growth signal transduction protein kinases. These proteins play an important role in regulating the MAP kinase signaling pathway. The signaling pathway affects cell differentiation, division, and secretion. Mutation in BRAF proteins can cause certain types of cancer including colorectal cancer and melanoma. Blocking mutated BRAF kinase proteins can help in inhibition of growth of cancerous cells. Hence, certain types of BRAF kinase inhibitors are used to treat a few types of cancer. BRAF kinase inhibitors are used as targeted therapy drugs for the treatment of non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and melanomas caused by mutations of the BRAF gene. These drugs directly target the BRAF protein and inhibit the growth of cancerous cells in patients with metastatic melanoma.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
BRAF Kinase Inhibitors Market – Competitive Landscape
The global BRAF Kinase inhibitors market is consolidated with very few global players accounting for major market share in international market. Leading biopharmaceutical companies have made significant investments in clinical research studies in to address the untapped market. In June 2017, the Food and Drug Administration (FDA) approved Dabrafenib and Trametinib regimen for the treatment of a rare subset of non?small-cell lung carcinoma (NSCLC)
Incorporated in 1863, Bayer AG is based in Leverkusen, Germany. It is a chemical and pharmaceutical company that markets products, helping prevent, diagnose, and treat diseases for humans and animals. The pharmaceutical division emphasizes on prescription products and specialty therapeutics in the areas of cardiology, women’s health, hematology, oncology, and ophthalmology.
F. Hoffmann-La Roche AG
Founded in 1896, F. Hoffmann-La Roche AG is headquartered in Basel, Switzerland. It is a global biopharmaceutical company engaged in the development, manufacture, and commercialization of pharmaceutical products and medical devices. Roche Pharmaceuticals is a world leader in biotechnology and oncology.
Novartis AG founded in 1996 in Switzerland is a global health care company that develops, manufactures, and provides high-quality drugs and health care services. The company operates through three business segments: innovative medicines, Sandoz, and Alcon. The company’s innovative medicines business division operates through two units: Novartis Pharmaceuticals and Novartis Oncology. The Novartis Oncology unit develops therapeutic treatments in the fields of oncology and rare diseases.
Array BioPharma Inc.
The Array BioPharma Inc. is the U.S. based biopharmaceutical company founded in the year 1998. The company is primarily focused of clinical research, development and commercialization of targeted small molecules drugs against the treatment of cancer and high burden disorders.
Expanding operations in future? To get the perfect launch ask for a custom report here
BRAF Kinase Inhibitors Market Dynamics
High prevalence of non-small-cell lung carcinoma (NSCLC) is likely to be key contributing factor for the growth of BRAF Kinase Inhibitors Market.
The BRAF kinase inhibitors market is primarily driven by increase in the rate of incidence and prevalence of cancers such as metastatic melanoma and non-small-cell lung carcinoma (NSCLC). Melanoma is reported as the most common type of cancer worldwide with estimated, age-standardized incidence rates of 2.8–3.1 per 100,000 people. According to the American Cancer Society, about 96,480 new patients with melanomas would be diagnosed in the U.S. by the end of 2019. Out of these, about 39,260 would be women and 57,220 would be men. About 7,230 people are expected to die of melanoma. According to a study published in ‘Cancer.Net’, lung cancer is the second-most common cancer and it is a leading cause of cancer deaths among both men and women. Around 142,670 deaths are likely to be caused by lung cancer by the end of 2019. Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer; it accounts for 84% of all lung cancer diagnoses.
Large number of clinical trial pipeline drugs and anticipated commercialization by various companies is one of the key driving factors during the forecast period.
The global BRAF kinase inhibitors market is expected to expand at a rapid pace during the forecast period. Research and development activities by key market players have increased over the last few years. They are focusing on extending the research on BRAF kinase inhibitors for other applications. Furthermore, several BRAF kinase inhibitor drugs are at the final stage of research and development and are expected to be launched during the forecast period.
BRAF Kinase Inhibitors Market – Segmentation
- Product Type
- Distribution Channel
BRAF Kinase Inhibitors Market – By Product Type
BRAF Kinase Inhibitors Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.